Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2020
Reporting Period: The filing serves as a disclosure of a corporate presentation current as of December 10, 2020, rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure referencing an attached presentation (Exhibit 99.1) rather than a financial statement containing quantitative data.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The primary purpose is to disclose the existence and content of a corporate presentation used for industry conferences.
Guidance, Outlook, and Risks
- Management Commentary: The Company provides summary business information via a "Corporate Presentation" attached as Exhibit 99.1.
- Forward-Looking Statements: The Company explicitly disclaims any obligation to correct or update the material in the Corporate Presentation in the future.
- Legal Status of Information: The information in the attached presentation is intended to be "furnished" and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) for actual business metrics and strategic outlook, as the 8-K text only references it.
- Verify the date of the presentation (December 10, 2020) to ensure data relevance given the disclaimer against future updates.
- Confirm the trading symbol (ORGO) on the Nasdaq Capital Market.
- Note that the Interim Chief Financial Officer, Henry Hagopian, signed the report.